Technical Analysis for LQDA - Liquidia Technologies, Inc.

Grade Last Price % Change Price Change
grade F 5.65 -5.68% -0.34
LQDA closed down 5.68 percent on Monday, August 19, 2019, on 2.1 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical LQDA trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction -5.68%
NR7 Range Contraction -5.68%
Lower Bollinger Band Walk Weakness -5.68%

Older signals for LQDA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology.
Health Biopharmaceutical Life Sciences Pharmaceutical Pharmaceutical Industry Pain Medication Clinical Trial Pulmonary Arterial Hypertension Two River Treprostinil
Is LQDA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 38.46
52 Week Low 5.5574
Average Volume 76,605
200-Day Moving Average 13.4579
50-Day Moving Average 7.6424
20-Day Moving Average 6.8215
10-Day Moving Average 6.545
Average True Range 0.6525
ADX 17.44
+DI 14.7483
-DI 26.0307
Chandelier Exit (Long, 3 ATRs ) 6.1025
Chandelier Exit (Short, 3 ATRs ) 7.5149
Upper Bollinger Band 7.9926
Lower Bollinger Band 5.6504
Percent B (%b) 0.0
BandWidth 34.335557
MACD Line -0.4761
MACD Signal Line -0.4073
MACD Histogram -0.0688
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.85
Resistance 3 (R3) 6.96 6.66 6.65
Resistance 2 (R2) 6.66 6.35 6.61 6.59
Resistance 1 (R1) 6.15 6.16 6.01 6.05 6.52
Pivot Point 5.86 5.86 5.78 5.80 5.86
Support 1 (S1) 5.35 5.55 5.20 5.25 4.78
Support 2 (S2) 5.05 5.36 5.00 4.71
Support 3 (S3) 4.55 5.05 4.65
Support 4 (S4) 4.45